Triple-negative breast cancer (TNBC) represents a challenge clinically due to the lack of actionable targets coupled with an aggressive disease course and a worse prognosis compared to other breast cancer subtypes. This book covers aspects of TNBC ranging from epidemiology, biology, molecular classification, to currently available and potentially new therapeutic options for TNBC. This book contains a range of recommended resources, including recent reviews, schematic illustrations, and information for patients with TNBC. Individuals including researchers and educators, practitioners, pharmaceutical professionals, patients as well as their family members will find this book useful.
Sample Chapter(s)
FRONT MATTER
Contents:
- Foreword by Zhi-Ming Shao
- Foreword by Yibin Kang
- About the Editors
- List of Contributors
- Abbreviations
- Overview of Triple-Negative Breast Cancer (Chanjuan Zheng, Guangchun He, and Xiyun Deng)
- Heterogeneity and Subtyping of Triple-Negative Breast Cancer (Yingying Wu, Qiuting Zhang, and Ceshi Chen)
- Genetics and Signaling Events in Triple-Negative Breast Cancer (Ying Li, Liang Zeng, and Faqing Tang)
- Epigenetics in Triple-Negative Breast Cancer (Ju Zhou, Sisi Chen, Md. Asaduzzaman Khan, Ting Xiao, Mousumi Tania, Md. Shamsuddin Sultan Khan, and Junjiang Fu)
- Biomarkers of Triple-Negative Breast Cancer (Qiujun Lu, Mi Wu, Cuiyan Wu, Meiling Liu, Faqing Tang, and Youyu Zhang)
- Clinical Aspects of Triple-Negative Breast Cancer (Doudou Huang, Jingyang Du, Xiaoxiang Guan, and Xiyun Deng)
- Novel Therapeutic Strategies of Triple-Negative Breast Cancer (Guifei Li, Hui Yao, Shichao Yan, Shujun Fu, Xiyun Deng, and Thomas J Rosol)
- Immunotherapy of Triple-Negative Breast Cancer (Huimei Yi, Yuan Tan, Lu Lu, Faqing Tang, and Xiyun Deng)
- Appendix: Online Resources
- Afterword
- Index
Readership: Individuals including undergraduate and graduate students, postdoctoral fellows, university researchers and educators, practitioners, pharmaceutical professionals, and patients who are interested in research and treatment of breast cancer.
Xiyun Deng is a professor of pathophysiology and molecular pathology and chair of Department of Basic Medical Sciences at Hunan Normal University School of Medicine located in Changsha, Hunan, China. He is the founder and currently serves as director of Key Laboratory of Translational Cancer Stem Cell Research at Hunan Normal University. Funded by the Natural Science Foundation of China (NSFC) and other funding agencies for over 15 years, his research interests cover the molecular mechanisms of cancer metastasis and, more recently, the experimental therapeutics targeting cancer stem cells. The major contributions he and his team have made over many years of research include: 1) the discovery that post-translational modifications of non-histone proteins play crucial roles in metastasis and drug-induced cellular stress responses in cancer stem cells; and 2) the development and mechanistic studies of cancer stem cell–targeting drugs against cancer with a particular focus on triple-negative breast cancer. He has published over 100 papers including first-author and/or corresponding-author articles/reviews in Blood, Clinical Cancer Research, Cancer Treatment Reviews, ACS Applied Materials & Interfaces, International Journal of Cancer, European Journal of Cancer, etc. As a research-oriented scholar, he is enthusiastically engaged in teaching activities. The undergraduates and graduates he mentored got several national-level awards including the "Challenge Cup" (2nd Prize), which is one of China's highest honors for undergraduates.
Faqing Tang is a professor of clinical pathology and laboratory medicine at Central South University, China. He serves as director of Clinical Laboratory and Medical Research Center, Hunan Cancer Hospital & the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University. He is director of Key Laboratory of Cancer Target Genes of Hunan Province, China. The research of the Tang laboratory focuses on the molecular carcinogenesis of cancer and the experimental therapeutics targeting oncogene. The major contributions he and his team have made include: 1) development and evaluation of new clinical laboratory technology, diagnostic reagents, and quality control software and approaches; 2) development of novel biomarkers for diagnosis/monitoring and therapeutic intervention of cancer including circulating tumor cells. He has published over 100 papers including first-author and/or corresponding-author articles in Cancer Research, Journal of Biological Chemistry, PLoS One, BMC Cancer, etc.
Thomas J Rosol is a professor of veterinary and toxicologic pathology, Chair of Biomedical Sciences at the Ohio University Heritage College of Osteopathic Medicine and diplomate of the American College of Veterinary Pathologists. He has served as dean of the College of Veterinary Medicine and senior associate and interim vice president for research at Ohio State University and on advisory boards to the National Institutes of Health, United States Department of Agriculture, EPA, American Veterinary Medical Association, and Morris Animal Foundation. Rosol serves as a consultant for industry in preclinical safety and toxicology in the areas of endocrine, bone, and reproductive pathology and animal models of cancer. The Rosol laboratory investigates the pathogenesis of animal models of human cancer, mechanisms and treatment of bone metastasis, and has been funded by NIH for 30 years. Recent work focuses on breast cancer and other cancer types, and automated pathology using image analysis and artificial intelligence algorithms. Rosol has over 300 publications and is an elected fellow of the American Association for the Advancement of Science and was recognized by Ohio State University as a Distinguished Scholar, which is one of the universities' highest honors.
